Brief: Xencor Presents Data From Multiple Preclinical XmAb Bispecific Antibody Programs, IL-12 Cytokine, XmAb662
12/11/2021 12:21
Nov 12 (Reuters) - Xencor Inc XNCR.O :
* XENCOR PRESENTS DATA FROM MULTIPLE PRECLINICAL XMAB®
BISPECIFIC
ANTIBODY PROGRAMS AND IL-12 CYTOKINE, XMAB662, AT THE SITC
ANNUAL MEETING
Source text for Eikon: ID:nBw19WPqZa
Further company coverage: XNCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xencor
See all newsXencor, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Brief: Xencor Q2 EPS USD -0.29
Brief: Xencor To Receive $105 Million From Alexion To Resolve Ultomiris® U.S. Royalty Matter
Xencor Q1 revenue falls sharply and misses estimates